Table 2 Knowledge of which conditions cfDNA screening is commercially available to detect stratified by provider type (n = 188)
OB/GYN (n = 114) % [95% CI] | MFM (n = 29) % [95% CI] | GP (n = 31) % [95%CI] | MW (n = 14) % [95% CI] | p-value | |
|---|---|---|---|---|---|
Correctly identified that cfDNA was able to screen for: | |||||
Trisomy 21 (Down Syndrome) | 95.6% [89.8–98.1] | 100.0% | 90.3% [73.4–96.9] | 85.7% [55.7–96.6] | p = 0.156 |
Trisomy 18 (Edwards Syndrome) | 93.0% [86.5–96.5] | 100.0% | 80.6% [62.6–91.2] | 85.7% [55.7–96.6] | p = 0.040 |
Trisomy 13 (Patau Syndrome) | 93.0% [86.5–96.5] | 96.6% [78.4–99.6] | 74.2% [55.8–86.8] | 71.4% [42.7–89.4] | p = 0.002 |
Monosomy X (Turner Syndrome) | 63.2% [53.8–71.2] | 86.2% [67.9–94.9] | 38.7% [23.2–57.0] | 42.9% [19.9–69.4] | p = 0.001 |
22q11.22 deletion (Di George Syndrome) | 23.7% [16.7–32.4] | 51.7% [33.7–69.3] | 29.0% [15.6–47.5] | 7.1% [0.9–39.2] | p = 0.007 |
Correctly identified that cfDNA was NOT able or commercially available to screen for: | |||||
Spina Bifida | 97.4% [92.1–99.2] | 100.0% | 87.1% [69.7–95.2] | 85.7% [55.7–96.6] | p = 0.020 |
Hirschsprung Disease | 100.0% | 100.0% | 100.0% | 100.0% | p = 1.0 |
Cystic Fibrosis | 95.6% [89.8–98.2] | 100.0% | 93.5% [77.0–98.4] | 100.0% | p = 0.485 |
Reported not knowing what conditions cfDNA screened for. | 4.9% [1.8–10.2] | 0.0% | 16.1% [6.7–33.8] | 21.4% [6.7–50.9] | p = 0.008 |